SCHEMBL6478488

SCHEMBL6478488

CCOC(=O)c1cc2cc(OC)c(O)cc2oc1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.64
KDM4E B2RXH2 6/20 0.64
GLA P06280 5/20 0.64
GAA P10253 5/20 0.64
ALDH1A1 P00352 4/20 0.64
HPGD P15428 4/20 0.64
CA12 O43570 3/20 0.64
CA7 P43166 3/20 0.64
CA9 Q16790 3/20 0.64
CA2 P00918 2/20 0.64
CA3 P07451 2/20 0.64
CA4 P22748 2/20 0.64
CA6 P23280 2/20 0.64
CA14 Q9ULX7 2/20 0.64
MAOA P21397 2/20 0.63
MIF P14174 1/20 0.63
PFKFB3 Q16875 1/20 0.63
NOD2 Q9HC29 1/20 0.63
CA5B Q9Y2D0 1/20 0.57
MAPT P10636 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25696493 0.87 MAOB (0.67) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL25235760 0.86 MAOB (0.65) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL25696561 0.85 MAOB (0.67) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL25243692 0.85 MAOB (0.64) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL1406249 0.84 KDM4E (0.76) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL1406180 0.83 MAOB (0.64) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL25203754 0.83 MAOB (0.64) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL6111808 0.83 MAOB (0.64) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL12967884 0.83 KDM4E (0.67) MAOBKDM4EGLAGAAALDH1A1
SCHEMBL25697038 0.83 MAOB (0.64) MAOBKDM4EGLAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951870-B2 Coumarin derivatives with COMT inhibiting activity ORION CORPORATION (FI) 2005-10-04 US disclosed
US-20040110750-A9 Coumarin derivatives with comt inhibiting activity ORION CORPORATION (FI) 2004-06-10 US disclosed
US-20030186975-A1 Coumarin derivatives with comt inhibiting activity PYSTYNEN JARMO (FI) 2003-10-02 US disclosed
EP-1301503-A1 COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY ORION CORPORATION (FI) 2003-04-16 EP disclosed
WO-2002002548-A1 COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY ORION CORPORATION (FI) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110750-A9 Coumarin derivatives with comt inhibiting activity COMT, CYP1A1, CYP2D6 MAOB 58/4885KDM4E 2539/4885GLA 1454/4885
US-20030186975-A1 Coumarin derivatives with comt inhibiting activity COMT, CYP1A1, CYP2D6 MAOB 58/4885KDM4E 2539/4885GLA 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.